IPN60090
IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers[1][2].
Product Specifications
CAS Number
1853164-83-6
UNSPSC
12352005
Target
Glutaminase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/gls1-in-1.html
Purity
99.47
Solubility
DMSO : 31.43 mg/mL (ultrasonic)
Smiles
O=C(NC1=NN=C(CC[C@@H](F)CN2N=NC(C(NC)=O)=C2)C=C1)CC3=NC(C)=CC(OC4CC(F)(F)C4)=C3
Molecular Formula
C24H27F3N8O3
Molecular Weight
532.52
References & Citations
[1]Maria Emilia Di Francesco, et al. Gls1 inhibitors for treating disease. WO2016004404A2.|[2]Michael J Soth, et al. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem. 2020 Nov 12;63 (21) :12957-12977.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
